Circulation 2003;108:833 8. 86. Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103:369 74. 87. Setsuta K, Seino Y, Takahashi N, et al. Clinical signi cance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 1999;84:608-11, A9. 88. Hudson MP, O Connor CM, Gattis WA, et al. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospec- tive analysis. Am Heart J 2004;147:546 52. Yancy et al. JACC Vol. 62, No. 16, 2013 2013 ACCF/AHA Heart Failure Guidelines: Executive Summary October 15, 2013:1495 539 89. Tang WH, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insuf ciency and survival. Am J Cardiol 2011;108:385 90. 90. de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60 8. 91. Lok DJ, van der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of brosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99:323 8. 92. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379 85. 93. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994;343:440 4. 94. Januzzi JL Jr., Sakhuja R, O Donoghue M, et al. Utility of amino- terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency depart- ment. 